PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26964390-2	2016	In ECD, central nervous system (CNS) and orbital lesions are frequent, and more than half of ECD pa tients carry the V600E mutation of the protooncogene BRAF.	Protactinium	97-99	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	153-157	
26321697-4	2015	The KIAA1549-BRAF fusion gene has been found in approximately 70% of PAs, but is reportedly rare in PMAs.	Protactinium	69-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17	
26321697-17	2015	In summary, no BRAF V600E mutations were found in PMSAs, but KIAA1549-BRAF fusion was identified in IPT, particularly in the PA component.	Protactinium	125-127	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	70-74	
24057326-11	2013	These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.	Protactinium	69-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	31-35	
25066317-3	2014	In our study we evaluated 51 PAs for BRAF duplication and BRAF V600E point mutation.	Protactinium	29-32	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	37-41	
25382612-3	2015	We detected the KIAA1549:BRAF fusion gene in five of 34 non-PA tumors (14.7%), that is, one glioblastoma, one anaplastic astrocytoma, one anaplastic pleomorphic xanthoastrocytoma, 1 ependymoma, and 1 Atypical Teratoid Rhabdoid Tumor.	Protactinium	60-62	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	25-29	
24554201-3	2014	Nevertheless, the most important causative factors seem to be NF1 gene inactivation, in cases related to neurofibromatosis type 1, and BRAF gene overexpression in sporadic PAs, both resulting in MAPK/Erk pathway upregulation.	Protactinium	172-175	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	135-139	
24057326-11	2013	These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.	Protactinium	69-72	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	176-180	
27792249-6	2017	As expected, BRAF mutations were detected in the aforementioned low-grade gliomas: in 4/27 PAs, 2/3 PXAs, 4/8 GGs, and 1/6 DNTs.	Protactinium	91-94	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17	
27389560-6	2016	The KIAA1549-BRAF fusion gene was detected only in 8 out of 11 PAs (73%) and in 3 out of 9 gangliogliomas (33%) (P=0.003).	Protactinium	63-66	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	13-17